The Lynx Group
Cholangiocarcinoma News

FDA Grants Accelerated Approval to Infigratinib for Metastatic Cholangiocarcinoma

June/July 2021, Vol 2, No 2

The FDA granted accelerated approval to the kinase inhibitor infigratinib (Truseltiq) for the treatment of adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma (CCA) that harbors an FGFR2 fusion or other rearrangement.

The approval was based on efficacy results from a phase 2, multicenter, open-label, single-arm clinical trial in which 108 patients with unresectable locally advanced or metastatic CCA and an FGFR2 fusion or rearrangement were treated with once-daily oral infigratinib 125 mg in 28-day cycles (21 consecutive days of treatment, followed by 7 days with no treatment).

All patients had received ≥1 previous treatments for CCA. For the trial, treatment continued until disease progression or unacceptable toxicity. Nearly all (99%) patients in the trial had stage IV CCA.

The primary study end points were overall response rate (ORR) and the duration of response (DOR), as determined by blinded Independent Central Review according to RECIST version 1.1.

The ORR was 23% (95% confidence interval [CI], 16-32), which included 24 partial responses and 1 complete response.

The median DOR was 5 months (95% CI, 3.7-9.3), with 8 of 23 responders maintaining a response for ≥6 months.

In a news release from QED Therapeutics and Helsinn Group that accompanied the FDA approval of infigratinib, Susan Moran, MD, MSCE, Chief Medical Officer for QED Therapeutics, said, “This is an important milestone for patients diagnosed with FGFR2 fusion–driven cholangiocarcinoma who have recurred after first-line therapy and are in need of targeted options for further treatment. Based on the efficacy seen to date, our team believes infigratinib possesses promise for a range of FGFR-driven conditions, including other cancers.”

During the study, the most common adverse reactions (observed in ≥20% of patients) were hyperphosphatemia, increased creatinine, nail toxicity, stomatitis, dry eye, fatigue, alopecia, palmar-plantar erythrodysesthesia syndrome, arthralgia, dysgeusia, constipation, abdominal pain, dry mouth, eyelash changes, diarrhea, dry skin, decreased appetite, vision blurred, and vomiting.

Serious risks identified in the study include hyperphosphatemia and retinal pigment epithelial detachment.

CCA News Editor-in-Chief Milind M. Javle, MD, Professor of Gastrointestinal Medical Oncology at The University of Texas M.D. Anderson Cancer Center, presented these study results at the 2021 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.

In the news release related to the FDA approval, Dr Javle noted that although “targeted treatments have extended survival for many types of cancer, people diagnosed with cholangiocarcinoma have previously been presented with extremely limited treatment options coupled with low statistical survival data.”

These study results confirmed that “infigratinib showed promise as a targeted treatment option for patients with FGFR2 fusion–driven cholangiocarcinoma with a well-tolerated safety profile in line with previous observations in this patient population,” Dr Javle added.

Related Items

Ivosidenib Approved for Advanced or Metastatic Cholangiocarcinoma
Web Exclusives
Ivosidenib has been approved by the FDA for adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 mutation as detected by an FDA-approved test.
Recent Developments in Genomic-Driven Therapies for Cholangiocarcinoma
June/July 2021, Vol 2, No 2
Personalized medicine has expanded the treatment options for patients with cholangiocarcinoma (CCA). At the 2021 Annual Meeting of the Cholangiocarcinoma Foundation (CCF), Ghassan K. Abou-Alfa, MD, MBA, Professor of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, discussed recent developments in personalized therapies, highlighting genomic alterations that are informing the new therapies for patients with CCA.
Futibatinib in Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Rearrangements: Primary Results of FOENIX-CCA2 Presented at AACR 2021
June/July 2021, Vol 2, No 2
The primary results of the phase 2 FOENIX-CCA2 clinical trial of futibatinib in patients with previously treated intrahepatic cholangiocarcinoma (CCA) and FGFR2 fusions or rearrangements were presented by Lipika Goyal, MD, MPhil, Assistant Professor of Medicine, Massachusetts General Hospital, Boston, at the 2021 Annual Meeting of the American Association for Cancer Research (AACR).
Truseltiq (Infigratinib) New Targeted Therapy FDA Approved for Advanced or Metastatic Cholangiocarcinoma Harboring FGFR2 Alterations
By Loretta Fala
June/July 2021, Vol 2, No 2
Cholangiocarcinoma (CCA) represents a group of heterogeneous cancers that originate in the bile ducts that connect the liver and gallbladder to the small intestine. Although the exact prevalence of CCA is unknown, CCA is a rare cancer; approximately 8000 new cases of CCA are diagnosed annually in the United States.
Incorporating FGFR Inhibitors into the Treatment Paradigm for Cholangiocarcinoma: Current Concepts and Future Directions
By Mitesh J. Borad, MD; Milind M. Javle, MD; Michael Morse, MD, FACP, MHS; Lewis R. Roberts, MB, ChB, PhD
June/July 2021, Vol 2, No 2
On January 15, 2021, experts in the management of patients with cholangiocarcinoma (CCA) convened for a virtual accredited continuing education satellite symposium held during the 2021 annual meeting of the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. The goal was to educate healthcare providers on various aspects of CCA, including epidemiology, current standards of care, unmet clinical needs, the safety and efficacy of fibroblast growth factor receptor (FGFR) inhibitors as second-line therapy, and practical approaches to incorporating FGFR inhibitors into the treatment paradigm for the disease.
The Latest Research in Biliary Tract Cancers Presented at ASCO GI 2021
March 2021, Vol 2, No 1
At the CCA Summit held during the 2021 ASCO Gastrointestinal (GI) Cancers Symposium, Rachna T. Shroff, MD, MS, Chief, Section of GI Medical Oncology, University of Arizona Cancer Center, Tucson, discussed 15 clinical trials that were presented at the ASCO GI Cancers Symposium on cholangiocarcinoma (CCA) and hepatobiliary diseases. She highlighted key advances related to chemotherapy, targeted therapies, and biomarkers in the management of biliary tract cancers, including CCA.
Derazantinib Beneficial in Patients with Intrahepatic Cholangiocarcinoma and FGFR2 Fusions: Early Results from FIDES-01
March 2021, Vol 2, No 1
In February 2021, Basilea Pharmaceuticals reported early results from the phase 2 FIDES-01 clinical trial (NCT03230318), which is evaluating the efficacy of derazantinib, an investigational small-molecule FGFR1-3 inhibitor, in patients with inoperable or advanced intrahepatic cholangiocarcinoma (CCA) and FGFR2 gene fusions or FGFR2 gene mutations or amplifications. Derazantinib also inhibits the colony-stimulating factor 1 receptor kinase (CSF1R). CSF1R-mediated signaling is important for the maintenance of tumor-promoting macrophages.
Targeted Therapies in Cholangiocarcinoma: Next-Generation Sequencing Is a Must
December 2020, Vol 1, No 3
The recent FDA approval of the first FGFR inhibitor, pemigatinib (Pemazyre), and the positive results from the phase 3 study of the first IDH1 inhibitor, ivosidenib (Tibsovo), represent major breakthroughs in the treatment of patients with cholangiocarcinoma (CCA), a rare cancer associated with poor outcomes. However, the duration of response with these agents is still relatively short.
FGFR Inhibition in Cholangiocarcinoma: Overcoming Acquired Resistance
December 2020, Vol 1, No 3
In April 2020, the FDA granted accelerated approval to pemigatinib (Pemazyre), the first targeted therapy for cholangiocarcinoma (CCA). The FGFR inhibitor was approved for adults with CCA and FGFR2 fusion.
Emerging Molecular Targets in Cholangiocarcinoma: IDH1, HER2, BRAF, and Beyond
December 2020, Vol 1, No 3
Targeted therapy has improved survival for patients with cancer across a broad spectrum of disease sites, but until recently, progress has been slow in the treatment of patients with cholangiocarcinoma (CCA).

Subscribe to CCA News

Stay up to date with personalized medicine by subscribing to receive the free CCA News print publication or weekly e‑Newsletter.

I'd like to receive: